Long-term clinical assessment of combined ACAC hemoperfusion-ultrafiltration in uremia.
ACAC hemoperfusion was used in series with a small fluid removal system for a clinical trial in the treatment of uremia. A 22-month trial included a pretest control period, test period and a post-test control period. The most significant observations from this trial are: 1) the predialysis body weight of the patient could be maintained closer to the patient's dry weight; 2) there was a significant increase in hematocrit; and 3) there was insufficient removal of urea. With the development of an effective urea removal system, a more compact artificial kidney than any presently available will become feasible.
D001774:Blood Chemical Analysis; D002214:Capsules; D002606:Charcoal; D003404:Creatinine / Q000097:blood; D005069:Evaluation Studies as Topic; D006464:Hemoperfusion / Q000295:instrumentation; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014462:Ultrafiltration / Q000295:instrumentation; D014511:Uremia / Q000097:blood / Q000628:therapy*; D014527:Uric Acid / Q000097:blood; D014882:Water-Electrolyte Balance
D002214:Capsules; D002606:Charcoal; D014527:Uric Acid; D003404:Creatinine